UBE2S

Across TCGA pan-cancer cohorts, UBE2S mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2S data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2S mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2S expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, OV, and LUAD are the cancer types where UBE2S mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.536	0.916	.007	10	view →
OV	DFS	Median	All	0.542	0.915	.027	4	view →
LUAD	OS	Median	III,IV	0.215	0.678	.008	3	view →
LSCC	DFS	Median	All	0.784	0.630	.044	2	view →
HNSC	OS	Tertile	II,III,IV	0.801	0.862	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBE2S–PDAC (DFS)

Open the PDAC breakdown →